Lantheus Holdings Inc (LNTH)

NASDAQ
Currency in USD
77.83
-2.31(-2.88%)
Closed·
After Hours
79.53+1.77(+2.28%)
·
LNTH Scorecard
Full Analysis
Management has been aggressively buying back shares
LNTH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
77.4180.04
52 wk Range
73.11126.89
Key Statistics
Edit
Prev. Close
80.14
Open
78.74
Day's Range
77.41-80.04
52 wk Range
73.11-126.89
Volume
1.07M
Average Vol. (3m)
1.05M
1-Year Change
-1.8%
Book Value / Share
16.97
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LNTH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
129.31
Upside
+66.14%
Members' Sentiments
Bearish
Bullish
ProTips
8 analysts have revised their earnings downwards for the upcoming period

Lantheus Holdings Inc News & Analysis

Show more

Lantheus Holdings Inc Company Profile

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer’s disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Lantheus Holdings Inc SWOT Analysis


Future Frontiers
Uncover Lantheus' growth prospects in Alzheimer's diagnostics and theranostics. Explore potential risks and opportunities shaping the company's long-term trajectory.
Market Maneuvers
Discover Lantheus' strategic partnerships and market positioning. Learn how the company navigates reimbursement challenges and competitive pressures in diagnostics.
Financial Flux
Delve into Lantheus' financial performance, including recent revenue challenges and strong profitability metrics. Analyst targets range from $110 to $159 per share.
Imaging Innovato
Lantheus Holdings leads in diagnostic imaging, with PYLARIFY driving growth. Explore its strategic expansion into Alzheimer's diagnostics and diverse product pipeline.
Read full SWOT analysis

Lantheus Holdings Inc Earnings Call Summary for Q1/2025

  • Lantheus Q1 2025 EPS of $1.53 and revenue of $372.8M miss estimates; stock drops 12.25% in pre-market trading
  • Revenue up 0.8% YoY, but operating profit and adjusted net income down 7.1% and 7.5% respectively; gross profit margin at 67%
  • 2025 revenue guidance of $1.55B-$1.585B; adjusted EPS guidance of $6.60-$6.70; double-digit revenue growth expected in 2026
  • Company focuses on PET diagnostics and radiotherapeutics; maintains strong financials with 64.4% gross profit margin and 35% 5-year revenue CAGR
  • Analysts set price targets from $110 to $166, suggesting upside potential despite current challenges
Last Updated: 05/07/2025, 09:16 AM
Read Full Transcript

Compare LNTH to Peers and Sector

Metrics to compare
LNTH
Peers
Sector
Relationship
P/E Ratio
21.2x−9.0x−0.5x
PEG Ratio
−0.460.090.00
Price / Book
4.6x3.3x2.6x
Price / LTM Sales
3.5x1.7x3.1x
Upside (Analyst Target)
67.0%84.7%51.1%
Fair Value Upside
Unlock3.0%8.9%Unlock

Analyst Ratings

12 Buy
1 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 129.31
(+66.14% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
1.53 / 1.64
Revenue / Forecast
372.76M / 377.79M
EPS Revisions
Last 90 days

LNTH Income Statement

People Also Watch

53.98
HALO
-1.03%
24.40
YOU
-3.90%
107.41
BDC
-3.03%
298.25
MEDP
-1.89%

FAQ

What Is the Lantheus Holdings Inc (LNTH) Stock Price Today?

The Lantheus Holdings Inc stock price today is 77.83

What Stock Exchange Does Lantheus Holdings Inc Trade On?

Lantheus Holdings Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Lantheus Holdings Inc?

The stock symbol for Lantheus Holdings Inc is "LNTH."

What Is the Lantheus Holdings Inc Market Cap?

As of today, Lantheus Holdings Inc market cap is 5.38B.

What Is Lantheus Holdings Inc's Earnings Per Share (TTM)?

The Lantheus Holdings Inc EPS (TTM) is 3.68.

When Is the Next Lantheus Holdings Inc Earnings Date?

Lantheus Holdings Inc will release its next earnings report on Jul 31, 2025.

From a Technical Analysis Perspective, Is LNTH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Lantheus Holdings Inc Stock Split?

Lantheus Holdings Inc has split 0 times.

How Many Employees Does Lantheus Holdings Inc Have?

Lantheus Holdings Inc has 808 employees.

What is the current trading status of Lantheus Holdings Inc (LNTH)?

As of Jun 16, 2025, Lantheus Holdings Inc (LNTH) is trading at a price of 77.83, with a previous close of 80.14. The stock has fluctuated within a day range of 77.41 to 80.04, while its 52-week range spans from 73.11 to 126.89.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.